(Q36831384)

English

Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.

scientific article published on 26 March 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 August 2017

Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. (English)

1 reference

Europe PubMed Central

16 August 2017

0 references

multiple myeloma

1 reference

based on heuristic

inferred from title

2

object named as

Frits van Rhee

0 references

7

object named as

Bart Barlogie

1 reference

Europe PubMed Central

16 August 2017

3

object named as

Elias Anaissie

1 reference

Europe PubMed Central

16 August 2017

Maurizio Zangari

1

object named as

Maurizio Zangari

1 reference

Europe PubMed Central

16 August 2017

author name string

Mauricio Pineda-Roman

4

1 reference

Europe PubMed Central

16 August 2017

Jeff Haessler

5

1 reference

Europe PubMed Central

16 August 2017

John Crowley

6

1 reference

Europe PubMed Central

16 August 2017

language of work or name

0 references

publication date

26 March 2008

1 reference

Europe PubMed Central

16 August 2017

British Journal of Haematology

1 reference

Europe PubMed Central

16 August 2017

141

1 reference

Europe PubMed Central

16 August 2017

433-444

1 reference

Europe PubMed Central

16 August 2017

4

1 reference

Europe PubMed Central

16 August 2017

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649864

29 September 2017

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649864

29 September 2017

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649864

29 September 2017

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649864

29 September 2017

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649864

29 September 2017

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649864

29 September 2017

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649864

29 September 2017

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649864

27 June 2018

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06982.X

21 January 2018

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06982.X

21 January 2018

Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06982.X

21 January 2018

Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06982.X

21 January 2018

Treatment options in metastatic renal carcinoma: an embarrassment of riches

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06982.X

21 January 2018

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06982.X

21 January 2018

DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06982.X

21 January 2018

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06982.X

21 January 2018

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06982.X

21 January 2018

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06982.X

21 January 2018

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06982.X

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06982.X

21 January 2018

Cytogenetic findings in 200 patients with multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18371114

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18371114

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18371114

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2141.2008.06982.X

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36831384&oldid=1522549602"